ADC development targeted at high-unmet-need indications, including lung and colon cancer
[by Yu, Suin] LigaChem Biosciences (hereafter referred to as LigaChem Bio) announced on September 9 that it had entered into a technology licensing agreement with the U.S.-based Go Therapeutics Inc. to license a novel anticancer antibody for the development of antibody-drug conjugate (ADC) candidates.
Through this agreement, 안전한 바카라 사이트 Bio has secured global rights to the development and commercialization of ADCs incorporating the antibody. Specific terms of the agreement remain undisclosed for contractual reasons.
The newly licensed antibody employs Go Therapeutics' next-generation technology to target a ‘super-clean target,’ an antigen expressed exclusively on tumor cells and absent from normal tissues. This approach addresses a key limitation of existing solid tumor treatments, namely ‘on-target toxicity,’ which occurs when target antigens are also expressed on normal cells. 안전한 바카라 사이트 Bio plans to develop this treatment for a range of solid tumors with significant unmet medical needs, including lung, breast, ovarian, and colon cancers.
"Including this antibody licensing agreement with Go Therapeutics, we have licensed five novel anticancer target antibodies in just this year alone. We will reinforce our joint research and strategic partnerships with Korean and international companies, expand beyond antibodies into innovative ADC payloads, and focus on building a novel ADC pipeline with strong potential for global technology transfer," said Kim Yong-zu, CEO of 안전한 바카라 사이트 Bio.
Conversely, 안전한 바카라 사이트 Bio aims to secure three to five new ADC candidates annually and rapidly advance them into clinical trials, in alignment with its ‘VISION 2030’ strategy of accelerated development. This licensing agreement forms part of that strategy, emphasizing the swift clinical entry of antibody-based ADCs and the continued acquisition of novel candidates.